Record Q3: Revenue Jumps 38% to $20.2M, Net Income Hits $3.7M
SLSN sits 48% above its 52-week low of $0.613.
Summary
Solésence posted Q3 2026 revenue of $20.2 million, up 38% from $14.6 million a year ago, and swung to record net income of $3.7 million from a $1.0 million loss. Gross margin expanded sharply to 39.3% from 23.8%, and adjusted EBITDA came in at $4.3 million versus a small negative a year ago. The quarter reverses the weak Q2 trend (revenue down 25% year-over-year) and follows the November 10 amended filings that restated 2023 through Q2 2026 for inventory costing errors. Cash remains thin at $1.3 million against $13.5 million of current liabilities, and the stock is under a Nasdaq delisting notice received September 29 after trading below $1.00 for 30 consecutive days. The 4:00 p.m. CT call today is the venue for any 2027 outlook and detail on the restatement cleanup.
At the time of this announcement, SLSN was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.2M. The 52-week trading range was $0.61 to $2.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.